Ken Cacciatore
Stock Analyst at TD Cowen
(1.33)
# 3,686
Out of 5,088 analysts
149
Total ratings
41.5%
Success rate
-0.4%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AUPH Aurinia Pharmaceuticals | Rated: Buy | $30 → $18 | $17.21 | +4.59% | 7 | Oct 21, 2026 | |
| TYO: 4502 Takeda Pharmaceutical Company Limited | Reiterated: Buy | ¥5,135 | ¥6,656 | n/a | 1 | Dec 19, 2024 | |
| TSX: BHC Bausch Health Companies Inc. | Downgraded: Hold | n/a | $12.41 | n/a | 6 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Reiterated: Buy | $30 → $25 | $20.01 | n/a | 6 | May 16, 2023 | |
| EYPT EyePoint | Reiterated: Buy | $35 | $0.38 | n/a | 3 | Jan 4, 2023 | |
| BHVN Biohaven | Reiterated: Buy | $25 | $16.49 | n/a | 1 | Nov 7, 2022 | |
| SUPN Supernus Pharmaceuticals | Reiterated: Buy | $35 → $40 | $41.84 | n/a | 10 | Aug 5, 2022 | |
| BLCO Bausch + Lomb | Reiterated: Buy | $35 | $20.40 | n/a | 2 | Jul 28, 2022 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $200 → $225 | $207.83 | n/a | 30 | May 5, 2022 | |
| AMRN Amarin Corporation | Reiterated: Buy | $10 → $9 | $12.74 | n/a | 7 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | CHF 41.36 → CHF 50.00 | CHF 2.99 | n/a | 2 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 → $25 | $8.52 | n/a | 6 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $9 | - | n/a | 4 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 → $4 | $20.00 | n/a | 2 | Aug 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $30 | $0.8984 | n/a | 11 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 → $250 | $1.83 | n/a | 7 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $3.53 | n/a | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $55 → $80 | $31.97 | n/a | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $3.42 | n/a | 4 | Dec 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 → $18 | $19.20 | n/a | 16 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $44.99 | n/a | 3 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $3 | $7.31 | n/a | 5 | May 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $45 | $0.000001 | n/a | 2 | Dec 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $55 → $7.5 | $10.36 | n/a | 3 | Jul 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 → $18 | $21.35 | n/a | 3 | May 7, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $21.31 | n/a | 1 | Oct 23, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $45.37 | n/a | 3 | May 5, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $2.54 | n/a | 1 | Jul 23, 2015 |
Aurinia Pharmaceuticals
Oct 21, 2026
Rated: Buy
Price Target: $30 → $18
Current: $17.21
Upside: +4.59%
Takeda Pharmaceutical Company Limited
Dec 19, 2024
Reiterated: Buy
Price Target: ¥5,135
Current: ¥6,656
Upside: n/a
Bausch Health Companies Inc.
Jun 16, 2023
Downgraded: Hold
Price Target: n/a
Current: $12.41
Upside: n/a
Takeda Pharmaceutical Company
May 16, 2023
Reiterated: Buy
Price Target: $30 → $25
Current: $20.01
Upside: n/a
EyePoint
Jan 4, 2023
Reiterated: Buy
Price Target: $35
Current: $0.38
Upside: n/a
Biohaven
Nov 7, 2022
Reiterated: Buy
Price Target: $25
Current: $16.49
Upside: n/a
Supernus Pharmaceuticals
Aug 5, 2022
Reiterated: Buy
Price Target: $35 → $40
Current: $41.84
Upside: n/a
Bausch + Lomb
Jul 28, 2022
Reiterated: Buy
Price Target: $35
Current: $20.40
Upside: n/a
Jazz Pharmaceuticals
May 5, 2022
Reiterated: Buy
Price Target: $200 → $225
Current: $207.83
Upside: n/a
Amarin Corporation
May 4, 2022
Reiterated: Buy
Price Target: $10 → $9
Current: $12.74
Upside: n/a
Mar 16, 2022
Reiterated: Buy
Price Target: CHF 41.36 → CHF 50.00
Current: CHF 2.99
Upside: n/a
Jan 10, 2022
Reiterated: Buy
Price Target: $23 → $25
Current: $8.52
Upside: n/a
Nov 16, 2021
Reiterated: Buy
Price Target: $20 → $9
Current: -
Upside: n/a
Aug 12, 2021
Reiterated: Buy
Price Target: $40 → $4
Current: $20.00
Upside: n/a
Aug 6, 2021
Reiterated: Buy
Price Target: $35 → $30
Current: $0.8984
Upside: n/a
Aug 5, 2021
Reiterated: Buy
Price Target: $9 → $250
Current: $1.83
Upside: n/a
Jul 12, 2021
Initiated Coverage: Buy
Price Target: $50
Current: $3.53
Upside: n/a
Feb 1, 2021
Reiterated: Buy
Price Target: $55 → $80
Current: $31.97
Upside: n/a
Dec 24, 2020
Reiterated: Buy
Price Target: $25
Current: $3.42
Upside: n/a
Nov 6, 2020
Reiterated: Hold
Price Target: $21 → $18
Current: $19.20
Upside: n/a
Apr 8, 2020
Reiterated: Buy
Price Target: $40
Current: $44.99
Upside: n/a
May 20, 2019
Downgraded: Hold
Price Target: $13 → $3
Current: $7.31
Upside: n/a
Dec 3, 2018
Reiterated: Buy
Price Target: $50 → $45
Current: $0.000001
Upside: n/a
Jul 9, 2018
Downgraded: Hold
Price Target: $55 → $7.5
Current: $10.36
Upside: n/a
May 7, 2018
Reiterated: Hold
Price Target: $21 → $18
Current: $21.35
Upside: n/a
Oct 23, 2017
Reiterated: Buy
Price Target: $16
Current: $21.31
Upside: n/a
May 5, 2016
Rated: Hold
Price Target: n/a
Current: $45.37
Upside: n/a
Jul 23, 2015
Reiterated: Buy
Price Target: $40
Current: $2.54
Upside: n/a